Anna Maria Fulghesu

List of Publications by Year in Descending Order

35 papers	921 citations	15 h-index	30 g-index
37 ext. papers	998 ext. citations	3.1 avg, IF	3.1 L-index

#	Paper	IF	Citations
35	Urinary Metabolites Reveal Hyperinsulinemia and Insulin Resistance in Polycystic Ovarian Syndrome (PCOS). *Metabolites*, **2021**, 11,	5.6	4
34	Polycystic Ovarian Morphology in Normocyclic Non-hyperandrogenic Adolescents. *Journal of Pediatric and Adolescent Gynecology*, **2021**, 34, 610-616	2	5
33	HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). *Gynecological Endocrinology*, **2020**, 36, 588-593	2.4	8
32	Very low dose of flutamide in the treatment of hyperandrogenism. *Gynecological Endocrinology*, **2018**, 34, 394-398	2.4	4
31	Diagnosis of Polycystic Ovarian Syndrome in Adolescence **2018**, 143-159		1
30	Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome. *Fertility and Sterility*, **2015**, 103, 808-14	4.8	11
29	Ovulation induction in young girls with menometrorragia: a safe and effective treatment. *Gynecological Endocrinology*, **2014**, 30, 117-20	2.4	6
28	The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome. *Gynecological Endocrinology*, **2011**, 27, 468-74	2.4	9
27	Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E204-8	5.6	44
26	Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. *Fertility and Sterility*, **2010**, 93, 2303-10	4.8	39
25	Diagnosis of metabolic disorders in women with polycystic ovary syndrome. *Obstetrical and Gynecological Survey*, **2008**, 63, 796-802	2.4	12
24	Hirsutism and hyperandrogenism associated with hyperreactio luteinalis in a singleton pregnancy: a case report. *Gynecological Endocrinology*, **2007**, 23, 248-51	2.4	21
23	Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. *Fertility and Sterility*, **2006**, 86, 398-404	4.8	29
22	N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. *Fertility and Sterility*, **2002**, 77, 1128-35	4.8	92
21	Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment. *Hormone Research in Paediatrics*, **2001**, 55, 224-8	3.3	13
20	A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. *Fertility and Sterility*, **2001**, 76, 326-31	4.8	120
19	Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study. *Journal of Endocrinological Investigation*, **2001**, 24, 483-90	5.2	13

18	Comment on "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome". *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2974-5	5.6	10
17	Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. *Metabolism: Clinical and Experimental*, **1999**, 48, 167-72	12.7	98
16	Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome. *Fertility and Sterility*, **1999**, 71, 462-7	4.8	7
15	Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. *Metabolism: Clinical and Experimental*, **1998**, 47, 158-62	12.7	21
14	Effect of maternal carbohydrate metabolism on fetal growth. *Obstetrics and Gynecology*, **1998**, 92, 8-12	4.9	40
13	Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1742-5	5.6	12
12	Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus. *Hormone Research in Paediatrics*, **1998**, 49, 263-8	3.3	7
11	Effect of pituitary adenylate cyclase-activating peptide on meiotic maturation in follicle-enclosed, cumulus-enclosed, and denuded rat oocytes. *Biology of Reproduction*, **1997**, 57, 1074-9	3.9	43
10	Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome. *Fertility and Sterility*, **1997**, 67, 34-9	4.8	14
9	Evidence of a disturbance of the hypothalamic-pltuitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. *Clinical Endocrinology*, **1996**, 45, 73-77	3.4	12
8	Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. *Fertility and Sterility*, **1995**, 64, 703-8	4.8	25
7	Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. *Fertility and Sterility*, **1995**, 63, 1195-9	4.8	44
6	Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome. *Human Reproduction*, **1994**, 9, 2242-6	5.7	8
5	Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. *Fertility and Sterility*, **1994**, 62, 35-41	4.8	36
4	Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. *Fertility and Sterility*, **1992**, 58, 296-301	4.8	51
3	Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. *Human Reproduction*, **1990**, 5, 143-9	5.7	54
2	Effect of luteal metoclopramide-induced hyperprolactinemia on pituitary and luteal responsiveness to gonadotropin-releasing hormone. *Hormone Research*, **1989**, 31, 169-74		1
1	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome		7